Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome) represents a potentially life-threatening hypersensitivity reaction characterized by fever, rash, lymphadenopathy, and systemic involvement. Unlike SJS/TEN with rapid onset, DRESS typically develops 2-8 weeks after drug exposure, and the presence of eosinophilia, atypical lymphocytes, and reactivated herpes viruses distinguishes this entity.
DRESS Syndrome represents a multisystem concern requiring integrated treatment approaches.
Etiology and Risk Factors
Understanding the molecular and cellular mechanisms underlying DRESS Syndrome guides precision therapeutics.
Pathophysiology
DRESS Syndrome develops through dysregulation of normal skin homeostatic mechanisms.
Clinical Features
Clinical manifestations of DRESS Syndrome vary substantially based on disease severity and individual factors.
Systemic Manifestations
Emerging therapies for DRESS Syndrome target specific pathophysiological mechanisms.
Diagnosis
Recognition of pathognomonic features enables accurate and timely diagnosis of DRESS Syndrome.
Management
Comprehensive DRESS Syndrome management addresses both disease manifestations and psychosocial impact.
Conclusion
Advanced treatment options for DRESS Syndrome address refractory cases and improve patient satisfaction.
Conclusion
Optimal care of DRESS Syndrome depends on accurate diagnosis, appropriate therapy selection, and ongoing clinical monitoring. Modern treatment options have substantially improved patient outcomes and quality of life. Regular communication with dermatology specialists ensures best results.